Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05843994 · ClinicalTrials.gov registry record
Artificial Intelligence Patient App for RDEB SCCs
A clinical trial of Epidermolysis Bullosa Dystrophica, sponsored by Northwestern University.
- Active
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT05843994 is a study of Epidermolysis Bullosa Dystrophica that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 20 participants, below the 41-participant average among 3 other Epidermolysis Bullosa Dystrophica trials with a reported enrollment target (51% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05843994, a study of Epidermolysis Bullosa Dystrophica, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, an artificial intelligence model to detect squamous cell carcinomas (SCC) on photos of recessive dystrophic epidermolysis bullosa (RDEB) skin is developed. The ultimate goal is to integrate this model into an app for patients and physicians, to help detect SCCs in RDEB early. SCCs which rapidly metastasize are the main cause of death in adults with RDEB. The earlier an SCC is recognized, the easier it can be removed and the better the outcome. AI leverages computer science to perform tasks that typically require human intelligence and has recently been used to identify skin cancers based on images. We are currently developing an AI approach for early detection of SCC and distinction of malignancy from chronic wounds and other RDEB skin findings. The aim is to create a web application for patients with RDEB to upload images of their skin and get an output as to SCC present/ no SCC. This will be especially valuable for patients with difficult access to medical expertise and those who are hesitant to allow full skin examination at each visit, often because of fear of biopsies. Thus, this project will directly benefit patients by allowing early recognition of SCCs and will empower patients and their families by providing a home use tool. So far, the study team has mainly used professional images (photographs taken in hospital settings by physicians, nurses, and clinical photographers) of both SCCs in RDEB and images of RDEB skin without SCC to develop and train the AI model. The images that are expected in a real-life setting will mostly be pictures taken by patients or family members with their phones or digital cameras. These images have different properties regarding resolution, focus, lighting, and backgrounds. Incorporating such images will be crucial in the upcoming phases of model development-testing and validation-for the web application be a success for patients.
Conditions Studied
Interventions
- OTHER online survey
Study Locations (1)
Illinois
- Department of Dermatology, Northwestern University Feinberg School of Medicine and Lurie Children's Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2028-11-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05843994
The ClinicalTrials.gov registry entry for NCT05843994 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 41-participant average among 3 other Epidermolysis Bullosa Dystrophica trials with a reported enrollment target (51% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epidermolysis Bullosa Dystrophica appearing as the primary indexed condition, and to 1 intervention - of which online survey is the first listed.
NCT05843994 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05843994 about?
NCT05843994 is a clinical study titled "Artificial Intelligence Patient App for RDEB SCCs". In this study, an artificial intelligence model to detect squamous cell carcinomas (SCC) on photos of recessive dystrophic epidermolysis bullosa (RDEB) skin is developed. The ultimate goal is to integrate this model into an app for patients and physicians, to help detect SCCs in RDEB early. SCCs wh...
What is the current status of trial NCT05843994?
This trial is currently active not recruiting. The enrollment target is 20 participants. The study started on 2023-01-30. Estimated completion is 2028-11-30.
What conditions does trial NCT05843994 study?
This clinical trial studies the following conditions: Epidermolysis Bullosa Dystrophica.
What interventions are being tested in trial NCT05843994?
The interventions under investigation include: online survey (OTHER).
Who is sponsoring clinical trial NCT05843994?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05843994 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epidermolysis Bullosa Dystrophica
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.